Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free OCSAW Stock Alerts

Oculis (OCSAW) Competitors

Oculis logo
$4.79 0.00 (0.00%)
As of 08/28/2026
Compare

OCSAW vs. SXTPW, BFRIW, CALA, CINGW, and CLVR

Should you buy Oculis stock or one of its competitors? Oculis's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Calithera Biosciences (CALA), Cingulate (CINGW), and Clever Leaves (CLVR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Oculis compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Oculis (NASDAQ:OCSAW) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Oculis N/A N/A N/A

In the previous week, 60 Degrees Pharmaceuticals and 60 Degrees Pharmaceuticals both had 1 articles in the media. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat Oculis' score of 1.87 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Oculis Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A
OculisN/AN/AN/AN/AN/A

Summary

60 Degrees Pharmaceuticals beats Oculis on 2 of the 2 factors compared between the two stocks.

How does Oculis compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Oculis (NASDAQ:OCSAW) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
OculisN/AN/AN/AN/AN/A

In the previous week, Biofrontera and Biofrontera both had 1 articles in the media. Biofrontera's average media sentiment score of 1.87 equaled Oculis'average media sentiment score.

Company Overall Sentiment
Biofrontera Very Positive
Oculis Very Positive

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Oculis N/A N/A N/A

Summary

Biofrontera beats Oculis on 1 of the 1 factors compared between the two stocks.

How does Oculis compare to Calithera Biosciences?

Oculis (NASDAQ:OCSAW) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

In the previous week, Oculis and Oculis both had 1 articles in the media. Oculis' average media sentiment score of 1.87 beat Calithera Biosciences' score of 0.00 indicating that Oculis is being referred to more favorably in the media.

Company Overall Sentiment
Oculis Very Positive
Calithera Biosciences Neutral

Company Net Margins Return on Equity Return on Assets
OculisN/A N/A N/A
Calithera Biosciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OculisN/AN/AN/AN/AN/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Summary

Oculis beats Calithera Biosciences on 1 of the 1 factors compared between the two stocks.

How does Oculis compare to Cingulate?

Cingulate (NASDAQ:CINGW) and Oculis (NASDAQ:OCSAW) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

In the previous week, Cingulate had 1 more articles in the media than Oculis. MarketBeat recorded 2 mentions for Cingulate and 1 mentions for Oculis. Oculis' average media sentiment score of 1.87 beat Cingulate's score of 0.44 indicating that Oculis is being referred to more favorably in the news media.

Company Overall Sentiment
Cingulate Neutral
Oculis Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
OculisN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
Oculis N/A N/A N/A

Summary

Cingulate and Oculis tied by winning 1 of the 2 factors compared between the two stocks.

How does Oculis compare to Clever Leaves?

Oculis (NASDAQ:OCSAW) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

In the previous week, Oculis had 1 more articles in the media than Clever Leaves. MarketBeat recorded 1 mentions for Oculis and 0 mentions for Clever Leaves. Oculis' average media sentiment score of 1.87 beat Clever Leaves' score of 0.00 indicating that Oculis is being referred to more favorably in the media.

Company Overall Sentiment
Oculis Very Positive
Clever Leaves Neutral

Oculis has higher earnings, but lower revenue than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OculisN/AN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
OculisN/A N/A N/A
Clever Leaves N/A N/A N/A

Summary

Clever Leaves beats Oculis on 3 of the 5 factors compared between the two stocks.

Get Oculis News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCSAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCSAW vs. The Competition

Export
MetricOculisPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.00B$7.11B$12.80B
Dividend YieldN/A2.62%2.54%11.27%
P/E RatioN/A785.14272.8425.46
Price / SalesN/A958.20685.44122.44
Price / CashN/A15.3228.7436.03
Price / BookN/A10.4311.016.31
Net IncomeN/A$2.83B$3.47B$349.45M
7 Day Performance-5.89%0.23%1.03%-0.23%
1 Month Performance25.07%5.50%8.03%4.24%
1 Year Performance-7.88%5.99%23.84%14.60%

Oculis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCSAW
Oculis
N/A$4.79
flat		N/AN/A$0.00N/AN/A32
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
+55.7%		N/A-58.7%$0.00$1.11MN/A2
BFRIW
Biofrontera
N/A$0.03
flat		N/A-81.6%$0.00$46.18MN/A70
CALA
Calithera Biosciences
N/A$0.00
+200.0%		N/A+50.0%$0.00N/AN/A60
CINGW
Cingulate
N/A$0.01
-31.6%		N/AN/A$0.00N/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:OCSAW) was last updated on 8/31/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel